Kloka, Jan Andreas
Friedrichson, Benjamin
Jasny, Thomas
Blum, Lea Valeska
Choorapoikayil, Suma
Old, Oliver
Zacharowski, Kai
Neef, Vanessa
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 19 November 2023
Accepted: 24 February 2024
First Online: 29 February 2024
Competing interests
: V.N. received honoraria for lectures and travel expenses from Sysmex, Pharmacosmos, MCN congress organisation, and support for publication costs from the Goethe University Frankfurt. K.Z. has received honoraria for participation in advisory board meetings for Haemonetics and Vifor and received speaker fees from CSL Behring, Masimo, Pharmacosmos, Boston Scientific, Salus, iSEP, Edwards and GE Healthcare. He is the Principal Investigator of the EU-Horizon 2020 project ENVISION (Intelligent plug-and-play digital tool for real-time surveillance of COVID-19 patients and smart decision-making in Intensive Care Units) and Horizon Europe 2021 project COVend (Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19). KZ leads as CEO the Christoph Lohfert Foundation as well as the Health, Patient Safety & PBM Foundation. J.A.K and B.F. are deputy principal investigators of ENVISION and COVend. All other authors declare no competing conflicts of interests.